Pharma BD Deal Intelligence
Bristol-Myers Squibb paid Bavarian Nordic $60M upfront for an option on PROSTVAC worth up to $975M, betting on a Phase 2 signal in prostate cancer immunotherapy, but the Phase 3 PROSPECT trial later failed to meet its overall survival endpoint in 2017.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bavarian Nordic announced it could receive up to $975 million including $60 million upfront, plus development, regulatory and commercialization milestones and…
GEN noted the deal size implied potential blockbuster framing for PROSTVAC, leveraging the Phase 2 8.5-month OS signal while acknowledging Phase 3 readout risk.
FierceBiotech reported Bavarian Nordic shares plummeted ~49% after the PROSPECT Phase 3 trial was halted for futility, with PROSTVAC failing to extend overall…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS gained an exclusive option to license PROSTVAC, Bavarian Nordic's Phase 3 PSA-targeting cancer immunotherapy. Bavarian Nordic received $60M upfront, with $80M option exercise plus up to $230M survival-tiered, $110M regulatory, and $495M sales milestones. Phase 3 PROSPECT trial later failed to meet OS endpoint (2017).
43K US cases/yr
Metastatic castration-resistant prostate cancer is advanced prostate cancer that has spread beyond the prostate and continues to progress despite testosterone-suppression therapy. Asymptomatic/minimally symptomatic mCRPC is the patient segment where life-prolonging therapy options expanded sharply in 2010-2014 but where unmet need for additional survival benefit remained substantial.
At deal time (March 2015), the asymptomatic/minimally symptomatic mCRPC space was already crowded with three life-extending agents and one immunotherapy: Provenge (sipuleucel-T, Dendreon) was the only approved cancer immunotherapy in this setting, with a 4.1-month median OS benefit (25.8 vs 21.7 months) but commercial struggles that drove Dendreon to bankruptcy in 2014; Zytiga (abiraterone, J&J), approved 2011, and Xtandi (enzalutamide, Astellas/Pfizer), approved 2012 with pre-chemo expansion in 2014, were the dominant oral hormonal agents and the de facto standard of care; Jevtana (cabazitaxel, Sanofi) and Xofigo (radium-223, Bayer) covered later-line options. PROSTVAC's Phase 2 had shown an 8.5-month OS delta — a much larger signal than Provenge's — and BMS's option-based deal ($60M upfront, $80M option exercise, up to $230M survival-tiered milestones) explicitly priced PROSTVAC's potential as a backbone immunotherapy that could combine with BMS's checkpoint franchise (Yervoy, Opdivo). The deal was viewed as strategically rational but high-risk given Provenge's commercial cautionary tale. The Phase 3 PROSPECT trial subsequently failed in September 2017 — overall survival was 34.8 months PROSTVAC vs 34.7 months placebo — and the program was discontinued, validating skeptics including short-seller Kerrisdale Capital who in 2015 had argued the Phase 2 OS delta was driven by baseline imbalances rather than true vaccine effect. Source: https://ascopubs.org/doi/10.1200/JCO.18.02031
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Bavarian Nordic A/S (PROSTVAC program) (this deal) | 2015 | $975M | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2015 deals · Bristol-Myers Squibb Company deals · Oncology deals